ulinastatin
AssetAlso called AER-002, BIKUNIN, MIRACLID, ESTOTIN
Inhibits serine proteases, including trypsin and neutrophil elastase, limiting inflammation and tissue injury.
- Stage
- Phase 1
- Modality
- Protein or enzyme
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Trial NCT07923578 is still running. Trial NCT07923578 updated in its registry on Nov 6, 2026. clinicaltrials.gov
Indications
1Ulinastatin
Phase 1, Not yet recruiting, NCT07923578, clinicaltrials.gov, Nov 7, 2026
In the full profile
- Owner and partners1
- Trials1
- Evidence for its targets1
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.